Generic Oseni Availability
Last updated on Apr 10, 2025.
Oseni is a brand name of alogliptin/pioglitazone, approved by the FDA in the following formulation(s):
OSENI (alogliptin benzoate; pioglitazone hydrochloride - tablet;oral)
-
Manufacturer: TAKEDA PHARMS USA
Approval date: January 25, 2013
Strength(s): EQ 12.5MG BASE;EQ 15MG BASE (discontinued) [RLD], EQ 12.5MG BASE;EQ 30MG BASE [RLD], EQ 12.5MG BASE;EQ 45MG BASE (discontinued) [RLD], EQ 25MG BASE;EQ 15MG BASE [RLD], EQ 25MG BASE;EQ 30MG BASE [RLD], EQ 25MG BASE;EQ 45MG BASE [RLD]
Is there a generic version of Oseni available?
An Authorized Generic version of Oseni has been approved. An Authorized Generic is a prescription drug that is produced by a brand company under a New Drug Application (NDA) and marketed as a generic under a private label. It is identical to the branded product in appearance and has exactly the same inactive ingredients.
List of authorized generic versions:
- Alogliptin Benzoate and Pioglitazone hydrochloride ORAL TABLET, FILM COATED 12.5; 30 mg/1; mg
Padagis Israel Pharmaceuticals Ltd
NDC Code: 458020260 - Alogliptin Benzoate and Pioglitazone hydrochloride ORAL TABLET, FILM COATED 25; 15 mg/1; mg
Padagis Israel Pharmaceuticals Ltd
NDC Code: 458020351 - Alogliptin Benzoate and Pioglitazone hydrochloride ORAL TABLET, FILM COATED 25; 30 mg/1; mg
Padagis Israel Pharmaceuticals Ltd
NDC Code: 458020402 - Alogliptin Benzoate and Pioglitazone hydrochloride ORAL TABLET, FILM COATED 25; 45 mg/1; mg
Padagis Israel Pharmaceuticals Ltd
NDC Code: 458020499
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Oseni. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Dipeptidyl peptidase inhibitors
Patent 7,807,689
Issued: October 5, 2010
Inventor(s): Zhang; Zhiyuan et al.
Assignee(s): Takeda Pharmaceutical Company Limited (Osaka, JP)The present invention provides a compound of the formula: ##STR00001## or stereoisomers or pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, articles of manufacture comprising the same, and methods of using the same.
Patent expiration dates:
- June 27, 2028✓✓✓
- June 27, 2028
-
Dipeptidyl peptidase inhibitors
Patent 8,173,663
Issued: May 8, 2012
Inventor(s): Feng Jun & Gwaltney Stephen L. & Stafford Jeffrey A. & Zhang Zhiyuan & Elder Bruce J. & Isbester Paul K. & Palmer Grant J. & Salsbury Jonathon S. & Ulysse Luckner G.
Assignee(s): Takeda Pharmaceutical Company LimitedCompounds, pharmaceuticals, kits and methods are provided for use with DPP-IV and other S9 proteases that comprise a compound comprising:
Patent expiration dates:
- March 15, 2025✓
- March 15, 2025
-
Dipeptidyl peptidase inhibitors
Patent 8,288,539
Issued: October 16, 2012
Inventor(s): Feng Jun & Gwaltney Stephen L. & Stafford Jeffrey A. & Zhang Zhiyuan & Elder Bruce J. & Isbester Paul K. & Palmer Grant J. & Salsbury Jonathon S. & Ulysse Luckner G.
Assignee(s): Takeda Pharmaceutical Company LimitedCompounds, pharmaceuticals, kits and methods are provided for use with DPP-IV and other S9 proteases that comprise a compound comprising:
Patent expiration dates:
- March 15, 2025✓
- March 15, 2025
-
Solid preparation comprising alogliptin and pioglitazone
Patent 8,637,079
Issued: January 28, 2014
Inventor(s): Nakamura Kenji & Kiyoshima Kenichiro & Nomura Junya
Assignee(s): Takeda Pharmaceutical Company LimitedA solid preparation containing compound (I), wherein the definition of compound (I) is as defined in the description, and pioglitazone, which is useful as a therapeutic drug for diabetes and the like and superior in the dissolution property, chemical stability and dissolution stability, is provided. A solid preparation containing the following first and second parts:
Patent expiration dates:
- June 4, 2029✓
- June 4, 2029
More about Oseni (alogliptin / pioglitazone)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (2)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: antidiabetic combinations
- En español
Patient resources
Professional resources
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
